argenx SE
(NASDAQ : ARGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -2.56%123.370.0%$413.90m
ICLRICON plc 3.92%217.722.8%$328.04m
VRXValeant Pharmaceuticals International, Inc. 0.38%28.7014.1%$168.87m
HZNPHorizon Therapeutics Plc 1.01%101.085.5%$131.51m
JAZZJazz Pharmaceuticals Plc 0.12%174.022.2%$88.44m
CTLTCatalent, Inc. 0.92%116.252.1%$77.95m
PRGOPerrigo Co. Plc 1.09%46.326.9%$51.39m
UTHRUnited Therapeutics Corp. -0.38%185.0814.0%$49.16m
ENDPEndo International Plc 1.43%4.968.6%$43.98m
BHCBausch Health Cos., Inc. 0.38%28.700.0%$43.89m
ARGXargenx SE -0.12%316.190.0%$40.67m
SAGESAGE Therapeutics, Inc. -1.62%45.037.6%$34.46m
IRWDIronwood Pharmaceuticals, Inc. 0.73%13.099.6%$28.49m
ZGNXZogenix, Inc. 3.65%17.877.5%$23.73m
AXSMAxsome Therapeutics, Inc. -3.74%53.791.9%$19.96m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.